Consistent with these previous observations, we observed copy gain and up-regulation of CKS1B, which is a cell cycle regulator that has been linked to and promotes cisplatin and other drug resistance in myeloma, breast cancer, and non-small cell lung cancer (20, 23, 29, 30). Here, CKS1B is linked to non-small cell lung carcinoma.